Fractyl Logo
Large Intestine

PIONEERING BREAKTHROUGH THERAPIES TO TREAT OBESITY, WEIGHT MAINTENANCE AFTER GLP-1S, AND TYPE 2 DIABETES (T2D)

Our vision is to develop breakthrough therapies that have the potential to prevent and reverse obesity, support durable weight maintenance after GLP-1 pharmacotherapy, and put T2D into remission . At Fractyl Health, we are singularly focused on developing therapies that are designed to target root causes of obesity and T2D, and delivering those therapies to patients as broadly and rapidly as possible. Our two therapies – Rejuva and Revita – have the potential to become a comprehensive approach to prevention and remission of both obesity and T2D, with the possibility of eradicating T2D entirely.

Duodenal Nutrient Sensing and Signaling
Duodenal Nutrient Sensing and Signaling
Duodenal Nutrient Sensing and Signaling
Duodenal Nutrient Sensing and Signaling

REVITA®

Revita is an outpatient procedural therapy designed to durably modify duodenal dysfunction via hydrothermal ablation in order to restore metabolic health.

In addition, early evidence suggests that Revita has the potential to provide durable weight maintenance after GLP-1s.

Learn About Revita

SEEKING A MAJOR ADVANCE IN GLP-1 MEDICINES WITH PANCREATIC GENE THERAPY

Rejuva is a novel, locally administered, AAV gene therapy platform currently in preclinical development to improve islet function. We believe the platform represents a major advance in incretin-based therapies. PGTx is designed to potentially enable long-term remission of T2D and obesity by durably altering metabolic hormone response in the pancreatic islet cells of patients with those diseases.

Learn about Rejuva
AAV-delivered glucagon-like peptide 1 receptor agonist (GLP1RA) gene therapy
AAV-delivered glucagon-like peptide 1 receptor agonist (GLP1RA) gene therapy